{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:25:58Z","timestamp":1773851158089,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jbo.2024.100617","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T22:49:01Z","timestamp":1718491741000},"page":"100617","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging"],"prefix":"10.1016","volume":"47","author":[{"given":"Suwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haojie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenglin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiachen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiezhu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8109-6347","authenticated-orcid":false,"given":"Junlin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jbo.2024.100617_b0010","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple Myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-021-00576-3","article-title":"Genomic characterization of functional high-risk multiple myeloma patients","volume":"12","author":"Soekojo","year":"2022","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.jbo.2024.100617_b0020","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.6004\/jnccn.2019.0049","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020","volume":"17","author":"Kumar","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"12","key":"10.1016\/j.jbo.2024.100617_b0025","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0030","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines\u00ae Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"10218","key":"10.1016\/j.jbo.2024.100617_b0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.jbo.2024.100617_b0040","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jbo.2024.100617_b0045","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.bbmt.2020.03.006","article-title":"Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients","volume":"26","author":"Blocka","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.jbo.2024.100617_b0050","first-page":"401","article-title":"Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02\/HO95 Study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jbo.2024.100617_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jbo.2024.100617_b0060","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jbo.2024.100617_b0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: How? When?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jbo.2024.100617_b0070","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2214\/ajr.160.5.8470574","article-title":"Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging","volume":"160","author":"Rahmouni","year":"1993","journal-title":"AJR Am. J. Roentgenol."},{"issue":"Suppl 2","key":"10.1016\/j.jbo.2024.100617_b0075","doi-asserted-by":"crossref","first-page":"38s","DOI":"10.2967\/jnumed.118.220582","article-title":"Radiomics: Data Are Also Images","volume":"60","author":"Hatt","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.jbo.2024.100617_b0080","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.7150\/thno.30309","article-title":"The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges","volume":"9","author":"Liu","year":"2019","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.jbo.2024.100617_b0085","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s11547-021-01388-y","article-title":"A preliminary study using spinal MRI-based radiomics to predict high-risk cytogenetic abnormalities in multiple myeloma","volume":"126","author":"Liu","year":"2021","journal-title":"Radiol. Med."},{"issue":"4","key":"10.1016\/j.jbo.2024.100617_b0090","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jmri.27637","article-title":"Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods","volume":"54","author":"Liu","year":"2021","journal-title":"J. Magn. Reson. Imaging"},{"key":"10.1016\/j.jbo.2024.100617_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105230","article-title":"Impact of feature harmonization on radiogenomics analysis: Prediction of EGFR and KRAS mutations from non-small cell lung cancer PET\/CT images","volume":"142","author":"Shiri","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"11","key":"10.1016\/j.jbo.2024.100617_b0100","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/leu.2015.209","article-title":"Defining and treating high-risk multiple myeloma","volume":"29","author":"Usmani","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jbo.2024.100617_b0105","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/bjh.16744","article-title":"Development of an RNA sequencing-based prognostic gene signature in multiple myeloma","volume":"192","author":"Zamani-Ahmadmahmudi","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.jbo.2024.100617_b0110","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.jbo.2024.100617_b0115","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0120","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1046\/j.1365-2141.2003.03948.x","article-title":"Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II","volume":"120","author":"Shaughnessy","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.jbo.2024.100617_b0130","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00277-014-2057-5","article-title":"Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study","volume":"93","author":"Oh","year":"2014","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.jbo.2024.100617_b0135","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images Are More than Pictures, They Are Data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"issue":"21","key":"10.1016\/j.jbo.2024.100617_b0140","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational Radiomics System to Decode the Radiographic Phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.jbo.2024.100617_b0145","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1007\/s00330-021-07793-1","article-title":"Radiomics signature on dynamic contrast-enhanced MR images: a potential imaging biomarker for prediction of microvascular invasion in mass-forming intrahepatic cholangiocarcinoma","volume":"31","author":"Zhou","year":"2021","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.jbo.2024.100617_b0150","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/536217","article-title":"3D texture analysis in renal cell carcinoma tissue image grading","volume":"2014","author":"Kim","year":"2014","journal-title":"Comput. Math. Methods Med."},{"issue":"12","key":"10.1016\/j.jbo.2024.100617_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121937","article-title":"Multi-Features Classification of Prostate Carcinoma Observed in Histological Sections: Analysis of Wavelet-Based Texture and Colour Features","volume":"11","author":"Bhattacharjee","year":"2019","journal-title":"Cancers (basel)"},{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40644-021-00433-3","article-title":"Magnetic resonance imaging-based radiomics signature for preoperative prediction of Ki67 expression in bladder cancer","volume":"21","author":"Zheng","year":"2021","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1016\/j.jbo.2024.100617_b0165","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1007\/s00261-021-03241-2","article-title":"Robustness and performance of radiomic features in diagnosing cystic renal masses","volume":"46","author":"K\u00f6nik","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"1","key":"10.1016\/j.jbo.2024.100617_b0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1148\/radiol.2019190407","article-title":"Radiomics versus Visual and Histogram-based Assessment to Identify Atheromatous Lesions at Coronary CT Angiography: An ex Vivo Study","volume":"293","author":"Kolossv\u00e1ry","year":"2019","journal-title":"Radiology"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137424000976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T08:22:49Z","timestamp":1723018969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137424000976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":34,"alternative-id":["S2212137424000976"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100617","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiomic nomogram for predicting high-risk cytogenetic status in multiple myeloma based on fat-suppressed T2-weighted magnetic resonance imaging","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2024.100617","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100617"}}